Suppr超能文献

抗硬化蛋白疗法和成骨不全对生长中和成年小鼠组织水平特性的影响,同时控制组织年龄。

Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.

作者信息

Sinder Benjamin P, Lloyd William R, Salemi Joseph D, Marini Joan C, Caird Michelle S, Morris Michael D, Kozloff Kenneth M

机构信息

Orthopaedic Research Laboratories, Department of Orthopaedic Surgery, University of Michigan Ann Arbor, MI, USA; Department of Biomedical Engineering, University of Michigan Ann Arbor, MI, USA.

Department of Chemistry, University of Michigan Ann Arbor, MI, USA.

出版信息

Bone. 2016 Mar;84:222-229. doi: 10.1016/j.bone.2016.01.001. Epub 2016 Jan 6.

Abstract

Bone composition and biomechanics at the tissue-level are important contributors to whole bone strength. Sclerostin antibody (Scl-Ab) is a candidate anabolic therapy for the treatment of osteoporosis that increases bone formation, bone mass, and bone strength in animal studies, but its effect on bone quality at the tissue-level has received little attention. Pre-clinical studies of Scl-Ab have recently expanded to include diseases with altered collagen and material properties such as osteogenesis imperfecta (OI). The purpose of this study was to investigate the role of Scl-Ab on bone quality by determining bone material composition and tissue-level mechanical properties in normal wild type (WT) tissue, as well as mice with a typical OI Gly➔Cys mutation (Brtl/+) in type I collagen. Rapidly growing (3-week-old) and adult (6-month-old) WT and Brtl/+ mice were treated for 5weeks with Scl-Ab. Fluorescent guided tissue-level bone composition analysis (Raman spectroscopy) and biomechanical testing (nanoindentation) were performed at multiple tissue ages. Scl-Ab increased mineral to matrix in adult WT and Brtl/+ at tissue ages of 2-4wks. However, no treatment related changes were observed in mineral to matrix levels at mid-cortex, and elastic modulus was not altered by Scl-Ab at any tissue age. Increased mineral-to-matrix was phenotypically observed in adult Brtl/+ OI mice (at tissue ages>3wks) and rapidly growing Brtl/+ (at tissue ages>4wks) mice compared to WT. At identical tissue ages defined by fluorescent labels, adult mice had generally lower mineral to matrix ratios and a greater elastic modulus than rapidly growing mice, demonstrating that bone matrix quality can be influenced by animal age and tissue age alike. In summary, these data suggest that Scl-Ab alters the matrix chemistry of newly formed bone while not affecting the elastic modulus, induces similar changes between Brtl/+ and WT mice, and provides new insight into the interaction between tissue age and animal age on bone quality.

摘要

组织水平的骨成分和生物力学是决定全骨强度的重要因素。硬化蛋白抗体(Scl-Ab)是一种用于治疗骨质疏松症的促合成代谢疗法候选药物,在动物研究中,它可增加骨形成、骨量和骨强度,但其对组织水平骨质量的影响却很少受到关注。Scl-Ab的临床前研究最近已扩展到包括胶原和材料特性改变的疾病,如成骨不全症(OI)。本研究的目的是通过测定正常野生型(WT)组织以及I型胶原具有典型OI Gly➔Cys突变(Brtl/+)的小鼠的骨材料成分和组织水平力学性能,来研究Scl-Ab对骨质量的作用。快速生长(3周龄)和成年(6月龄)的WT和Brtl/+小鼠用Scl-Ab治疗5周。在多个组织年龄阶段进行荧光引导的组织水平骨成分分析(拉曼光谱)和生物力学测试(纳米压痕)。Scl-Ab在2-4周龄的成年WT和Brtl/+小鼠中增加了矿物质与基质的比例。然而,在皮质中部未观察到与治疗相关的矿物质与基质水平变化,并且在任何组织年龄阶段,Scl-Ab均未改变弹性模量。与WT相比,在成年Brtl/+ OI小鼠(组织年龄>3周)和快速生长的Brtl/+(组织年龄>4周)小鼠中,从表型上观察到矿物质与基质增加。在由荧光标记定义的相同组织年龄下,成年小鼠的矿物质与基质比例通常低于快速生长的小鼠,且弹性模量更大,这表明骨基质质量可受动物年龄和组织年龄的共同影响。总之,这些数据表明,Scl-Ab改变了新形成骨的基质化学性质,同时不影响弹性模量,在Brtl/+和WT小鼠之间诱导了相似的变化,并为组织年龄和动物年龄对骨质量的相互作用提供了新的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49bb/4757447/7c7a286e7d35/nihms749563f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验